Clinical Trial Update: Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

View source ↗

Summary

Post-marketing surveillance study in Korea to evaluate the safety and effectiveness of Xultophy (insulin degludec/liraglutide) in adults with type 2 diabetes in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Xultophy (insulin degludec and liraglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED